Mutations in isocitrate dehydrogenase 1/2 (IDH1/2 MT ) are drivers of a variety of myeloid neoplasms. As they yield the same oncometabolite, D-2-hydroxyglutarate, they are often treated as equivalent, and pooled. We studied the validity of this approach and found IDH1/2 mutations in 179 of 2119 myeloid neoplasms (8%). Cross-sectionally, the frequencies of these mutations increased from lower-to higher risk disease, thus suggesting a role in clinical progression. Variant allelic frequencies indicated that IDH1 MT and IDH2 MT are ancestral in up to 14/74 (19%) vs 34/99 (34%; P = 0.027) of cases, respectively, illustrating the pathogenic role of these lesions in myeloid neoplasms. IDH1/2 MT was associated with poor overall survival, particularly in lower risk myelodysplastic syndromes. Ancestral IDH1 MT cases were associated with a worse prognosis than subclonal IDH1 MT cases, whereas the position of IDH2 MT within clonal hierarchy did not impact survival. This may relate to distinct mutational spectra with more DNMT3A and NPM1 mutations associated with IDH1 MT cases, and more ASXL1, SRSF2, RUNX1, STAG2 mutations associated with IDH2 MT cases. Our data demonstrate important clinical and biological differences between IDH1 MT and IDH2 MT myeloid neoplasms. These mutations should be considered separately as their differences could have implications for diagnosis, prognosis and treatment with IDH1/2 MT inhibitors of IDH1/2 MT patients.
INTRODUCTION
Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 MT and IDH2 MT ) are implicated in the development of numerous types of cancer, including glioma, chondrosarcoma, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, melanoma and certain myeloid neoplasms. 1 Within myeloid malignancies, IDH1/2 MT are present in a significant proportion of acute myeloid leukemia (AML) and, while less common, in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). 2, 3 IDH1/2 MT impart a gain of function by causing single amino acid changes in the active sites of the enzymes. Whereas (wild-type) IDH1/2 WT convert isocitrate and NADP + to α-ketoglutarate (αKG) and NADPH, IDH1/2 MT convert NADPH and αKG to NADP + and D-2-hydroxyglutarate (D-2HG). 4 D-2HG and αKG have similar structures; resultant D-2HG accumulation in IDH1/2 MT cells inhibits many αKG-dependent dioxygenases, such as TET2 DNA hydroxyl demethylases 5, 6 and Jumonji domain containing histone demethylases (for example, KDM6A/UTX and KDM3B/ JMJD1B). Dysfunction of these enzymes is considered to be responsible for global DNA hypermethylation, inhibition of differentiation, and preservation of stemness. 7, 8 In addition, D-2HG activates, rather than inhibits egg laying defective nine (EGLN), which induces HIF1α degradation and growth factorindependent proliferation. 9, 10 As direct evidence that IDH1/2 MT are oncogenic, introduction of IDH2 R140Q or IDH2 R172K into 10T1/2 mesenchymal progenitor cells yielded an AML-like disease in mice. [11] [12] [13] IDH2 R140Q was also necessary for AML maintenance in mice, 12 indicating that IDH1/2 MT may be useful as therapeutic targets. These findings motivated the development of specific inhibitors of IDH1/2 MT enzymes. [14] [15] [16] [17] [18] The inhibitors that are currently in clinical trials, AG-221 that targets IDH2 R140Q and AG-120 that targets IDH1 R132H , restrict the production of D-2HG and thereby induce differentiation of AML cells ex vivo. 15 Both agents have shown promising preliminary results in phase I clinical trials. 19 Genomic studies of molecular landscapes in human cancer have frequently combined IDH1 MT and IDH2 MT as a single functional group despite physiological differences: IDH1 is localized in the cytosol and IDH2 in the mitochondrial matrix. Remarkably, the spectrum of cancers and their subtypes differ in the distribution of IDH1/2 MT . IDH1 MT predominates in glioma (95%), chondrosarcoma (95%) and cholangiocarcinoma (80%), whereas the IDH1 MT :IDH2 MT ratio is more balanced or even skewed toward a higher frequency of IDH2 MT in AML. 1 In addition, only IDH2 MT have been reported in angioimmunoblastic T-cell lymphoma, osteosarcoma and gastric cancer, again suggesting that there are pathophysiologic differences between IDH1 MT and IDH2 MT . Biochemical investigations have shown that the specific amino acid substitutions IDH1 R132H , IDH1 R132C , IDH2 R140Q and IDH2 R172K differ in D-2HG production potency. IDH2 R172K is the most potent, followed by IDH1 R132H , IDH1 R132C and IDH2 R140Q . There are more than 60 different αKG-dependent dioxygenases that can theoretically be inhibited by D-2HG with likely distinct IC 50 . Thus, different IDH1/2 MT inhibit different sets of αKG-dependent enzymes and this may partially explain differing distributions of IDH1/2 MT between cancers. 1 To investigate the clinical impact of IDH1/2 MT in myeloid neoplasms, we studied a cohort of 2119 patients with myeloid neoplasms. We performed whole-exome/targeted multiamplicon sequencing on the samples obtained from these patients from different institutions. We compared the mutational landscapes of IDH1 MT and IDH2 MT samples, their clinical associations, overall patient survival and clonal hierarchies. Our aim was to provide insights into IDH1/2 MT myeloid malignancy pathogenesis, especially with respect to the clonal architecture of IDH1/2 MT cases, and to determine whether IDH1 MT and IDH2 MT should be grouped or considered separately, particularly with respect to the potential benefits of IDH1/2 MT inhibitors in various clinical contexts.
MATERIALS AND METHODS

Patient population
Blood and bone marrow samples were obtained from 2119 patients diagnosed with lower risk MDS (868) and higher risk MDS (536), defined as per World Health Organization classification; secondary AML (sAML; 153); MPN (63); MDS/MPN (165); or primary AML (pAML; 334). From this cohort, 418 samples from 409 patients were subjected to whole-exome sequencing (WES). Furthermore, 1815 samples from 1761 patients were tested for a subset of genes (including IDH1 and IDH2; Supplementary  Table S1 ) by using targeted sequencing (TS). The total of 2179 samples listed above is greater than our total of 2119 samples because serial samples of 60 patients were included in the analysis. The sum of 409 patients subjected to WES and 1761 patients subjected TS is larger than 2119 because the WES and TS cohorts are partially overlapping.
Informed consent was obtained from patients according to protocols approved by the institutional review boards and in accordance with the Declaration of Helsinki. These patients were seen and treated at the Cleveland Clinic, the University of Tokyo and the Munich Leukemia Laboratory, diagnosis was confirmed on the basis of World Health Organization classification criteria. Patients with refractory anemia (RA), RA with ringed sideroblasts (RARS), refractory cytopenias with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts (RCMD-RS) and MDSunclassifiable (MDS-u) were classified as lower risk MDS. Those with RA with excess blasts (RAEB-1 and RAEB-2) were classified as higher risk MDS. Details of MDS/MPN and MPN subcategories are provided in Supplementary Table S2 . Clinical details of the patients, including blood counts, demographics and survival times, were obtained from medical records.
Sequencing technology
DNA was obtained from tumor and germline paired samples. For WES, the 50 Mb of protein-coding sequences was enriched from total genomic DNA by liquid-phase hybridization using SureSelect (version 4; Agilent Technology, Santa Clara, CA, USA), followed by massively parallel sequencing with HiSequation 2000 (Illumina, San Diego, CA, USA). Somatic mutations were called as previously described, 20,21 using the GATK algorithm (Broad Institute). To minimize false positives and focus on the most prevalent or relevant somatic events, we implemented a rational bioanalytic filtering approach and applied heuristic bioanalytic pipelines. For confirmation of somatic mutations, we analyzed paired germline DNA from CD3 + lymphocytes. For TS of a specific panel of genes, we applied multi-amplicon deep sequencing (TrueSeq; Illumina) to frequently-affected exons of 60 selected genes. The sequencing libraries were generated according to an Illumina paired-end library protocol and subjected to deep sequencing on MiSeq (Illumina) instrumentation according to standard protocol. Copy number information at the locus of each mutation was assessed as previously reported. 22 For samples sequenced in Munich, 104 known or putative mutational gene targets in MDS were examined for mutations from the cohort by using massively parallel sequencing (Illumina) or SureSelect (Agilent) captured target sequences. 23 Highprobability oncogenic mutations were called by eliminating sequencing/ mapping errors and known/possible single-nucleotide polymorphisms based on available databases and frequencies of variant reads. Genomic copy number status was calculated by directly enumerating corresponding sequencing reads in each exon.
Analysis of clonal architecture
Variant allelic frequencies (VAF) were calculated as the fraction of mutated reads of the total number of reads of a certain gene. VAFs were adjusted by using copy number information at the locus of each mutation. We recapitulated the clonal architecture of a patient using these copy numberadjusted VAFs. Ancestral vs subclonal events were determined using a copy number-adjusted VAF difference between two events, with a higher VAF indicating ancestral origin. We used a VAF threshold of 5% (absolute) to reliably discriminate ancestral from subclonal events. Competing genetic events below this threshold were considered to be of undeterminable ancestry. This threshold was chosen based on previous studies 24 and statistical calculations of our own data, based on the average depth of sequencing in our samples.
Statistical analysis
Comparisons of proportions were performed using the χ 2 and Fisher's exact tests and differences in values and in ranks were assessed by Student t-tests and Mann-Whitney U tests, respectively. Cox models were used to identify correlates with overall survival. Kaplan-Meier curves were generated to graphically depict survival differences. Throughout, two-sided tests were used with significance defined as αo.05. These analyses were performed using SPSS (IBM Inc., Armonk, NY, USA), GraphPad Prism 6 (Graphpad Software Inc., La Jolla, CA, USA) and the R statistical programming language.
RESULTS
Clinical characterization of IDH1/2 mutations
Among the 2119 patient samples tested (Table 1) , we identified IDH1 and IDH2 mutations in 78 (4%) and 101 (5%) cases, respectively, in a mutually exclusive fashion. Of the IDH1 MT cases, IDH1 R132C (50%, n = 39) and IDH1 R132H (38%, n = 30) were the most common; 12% (n = 9) harbored other IDH1 R132 mutations (IDH1 R132X ). Amongst IDH2 MT cases, IDH2 R140Q (85%, n = 84) was the most frequent mutation, followed by IDH2 R140X (5%, n = 5), IDH2 R172K (9%, n = 9) and IDH2 R172W (1%, n = 1) ( Figure 1a ). IDH1 MT patients were younger than IDH1/2 WT patients (P = 0.01), an observation similar to that reported for IDH1 MT glioblastoma patients. 25 Across the spectrum of MDS, the frequency of IDH1/2 MT increased with progression, as IDH1 MT occurred in 2% of lower risk MDS cases, in 3% of higher risk MDS cases and in 7% of sAML cases. IDH2 MT frequency increased as MDS progressed (in 2% of lower risk MDS, in 7% of higher risk MDS and in 6% of sAML cases). The average number of mutations in each of these categories as determined by WES did not increase as much with 21, 30 and 27, respectively (Supplementary Figure S1 ). These findings suggest that in IDH1/2 MT MDS cases, a high proportion of IDH1/2 MT are associated with progression to advanced disease. In addition, IDH1 and IDH2 mutation frequencies were relatively lower in MDS/MPN and MPN patients, and showed the highest frequency in pAML patients (Figure 1b ). While IDH2 MT were enriched for a normal karyotype, IDH1 MT patients more often had a deletion of chromosome Y in comparison with IDH1/2 WT patients. Other clinical characteristics were similar between IDH1/2 MT and IDH1/2 WT patients (Table 1 ; Supplementary Table S3 ). More detailed clinical information on IDH1 MT and IDH2 MT patients with myeloid malignancies is shown in Supplementary Tables S4  and S5 .
Molecular characterization of IDH1-and IDH2-mutated myeloid neoplasms To characterize the molecular features of patients with myeloid neoplasms with IDH1 MT or IDH2 MT , we analyzed associations between IDH1/2 MT and other mutational events (Figure 2a ; Supplementary Table S6 ). Overall, NPM1 mutations were more frequent in both IDH1 MT and IDH2 MT cases, compared with IDH1/2 WT patients (Figure 2b and Supplementary Tables S6-8 ).
Other somatic events were not significantly associated with both IDH1 MT and IDH2 MT cases compared with IDH1/2 WT cases.
When IDH1 MT cases were compared with IDH1/2 WT cases, they were enriched for DNMT3A (P o 0.0001), PHF6 (P = 0.0006) and FLT3 (P = 0.0195) mutations, whereas IDH2 MT cases were enriched for ASXL1 (P o 0.0001), SRSF2 (P o0.0001), RUNX1 (P = 0.0034) and STAG2 (P o0.0001) compared with IDH1/2 WT cases. NPM1 mutations occurred more frequently in IDH1 MT patients than in IDH2 MT patients (P = 0.045), whereas IDH2 MT patients were enriched for ASXL1 (P = 0.016), SRSF2 (P = 0.007) and STAG2 (P = 0.019) mutations compared with IDH1 MT patients. Cohesin complex mutant carriers (STAG2, RAD21, SMC3) were more frequent in IDH1 MT (P = 0.025) and IDH2 MT (P o 0.0001) cases compared with IDH1/2 WT cases. Conversely, SF3B1 and TET2 mutations occurred less frequently in IDH1 MT (Po 0.0001 and P = 0.023) and in IDH2 MT (P o 0.0001 and P o 0.0001) cases than in IDH1/2 WT cases. Although we observed a negative correlation between IDH1 and TET2 mutations, TET2 mutations, if present, were less infrequent in IDH1 MT patients than in IDH2 MT patients (P = 0.027; Figure 2c ).
Analysis of ancestry and clonal architecture of IDH1/2-mutated patients Using copy number-adjusted VAF, we reconstructed the clonal architecture of IDH1/2 MT patients to establish whether an IDH1 MT or IDH2 MT was an ancestral or subclonal mutation. Clonal hierarchy was further confirmed and refined by serial analyses, performed in Figure 1 . Breakdown of IDH1/2 mutations among disease types and specific amino acid substitutions. (a) Pie chart showing the percentages of the specific IDH1/2 mutational amino acid substitutions in the cohort. (b) Frequencies of IDH1 and IDH2 mutations in various myeloid neoplasms. pAML, primary acute myeloid leukemia; sAML, secondary acute myeloid leukemia. IDH1 R132X denotes IDH R132 mutations other than IDH1 R132H or IDH1 R132C . IDH2 R140X denotes IDH2 R140 mutations other than IDH2 R140Q . 60 exemplary cases. IDH1 MT and IDH2 MT were ancestral in 19% and 34% of IDH1/2 MT patients and subclonal in 55% and 45%, respectively ( Figure 3a) . As we used a cut-off value of 5% (absolute) in VAF difference, the ancestral vs subclonal status of some IDH1/2 MT remained 'undetermined' when there were small VAF differences between IDH1/2 mutations and other mutations (see Methods). A lower proportion of IDH1 MT cases were of ancestral origin compared with IDH2 MT cases (P = 0.027). We also observed differences in the clonal succession between specific IDH1/2 MT variants (Figure 3b ). Although IDH1 R132H and IDH1 R132C mutations were ancestral in equal frequencies (22% and 21%), other IDH1 mutations (IDH1 T98I (n = 1), IDH1 R132L (n = 1) and IDH1 R132S (n = 5)) occurred only as subclonal events. Similarly, IDH2 R140Q mutations were ancestral in 39% of IDH2 R140Q -mutated cases, whereas other IDH2 R140 mutations (IDH2 R140L (n = 2) and IDH2 R140W (n = 3)) were always subclonal. IDH2 R172 mutations were ancestral in only 10% of IDH2 R172 -mutated patients. In the different types of myeloid neoplasms, we did not observe differences in the distribution between ancestral and subclonal IDH1/2 MT and there was no difference in the mean VAF of IDH1 MT vs IDH2 MT ( Supplementary Figures S2A-C) . We observed higher IDH1/2 MT VAFs in patients with ancestral IDH1/2 MT than subclonal IDH1/2 MT (Figure 3c and Supplementary Figure S2D ). IDH1/2 MT VAFs were highest in patients with IDH1/2 MT of undeterminable ancestry, which may reflect a higher disease burden in patients when IDH1/2 MT cooperate with other mutations. WES analyses revealed that IDH1 MT and IDH2 MT were ancestral in 1/21 (5%) and 2/24 (8%) of IDH1/2 MT cases, respectively, whereas TS suggested that IDH1 MT and IDH2 MT were ancestral in 13/53 (25%) and 32/75 (43%) of cases (P = 0.0002). This difference probably reflects missed ancestral mutations in the TS samples ( Supplementary Table S9 ). The clonal architecture of representative IDH1/2 MT patients (out of 60 studied) that were serially sequenced is shown in Figure 3d and Supplementary Figure S2E . In subclonal IDH1/2 MT cases, we investigated the corresponding ancestral events. These analyses showed heterogeneity, with 19 and 20 different ancestral mutations in 35 and 38 cases with subclonal IDH1 MT or IDH2 MT , respectively. Subclonal IDH1 MT were most often preceded by an ancestral DNMT3A mutation (30%; Supplementary Figure S2F ), whereas ancestral RUNX1 mutations most frequently preceded a subclonal IDH2 MT (17%; Supplementary  Figure S2G ). We observed a RUNX1 mutation preceding a subclonal IDH1 MT only once. Hierarchical clonal analyses of neoplasms with undeterminable IDH1/2 MT clonal architecture (small VAF differences between IDH1/2 mutations and other mutations) may provide insight into which mutations cooperate (in the case of enrichment of co-occurring mutations; Figure 2 ) or compete (in the case of mutual exclusivity with co-occurring mutations) with IDH1/2 MT . DNMT3A mutations were most frequently the 'main competitor' of IDH1 MT and IDH2 MT of undetermined ancestry ( Supplementary Figures S2H-I) . We did not observe a single RUNX1 mutation that competed with IDH2 MT , indicating that VAF differences between ancestral RUNX1 mutations and subclonal IDH2 MT , and vice versa, are rather large.
Prognostic effects of IDH1/2 mutations in myeloid neoplasms In our cohort, IDH1/2 MT were associated with worse overall survival (Figure 4a ). In subset analyses, we observed that IDH1/2 MT were significantly associated with reduced median overall survival in lower risk MDS patients (41 vs 66 months, P = 0.03), but not in higher risk MDS (34 vs 30 months, P = 0.91), sAML (26 vs 19 months, P = 0.74) or pAML patients (20 vs 16 months, P = 0.79; Figures 4b-e ). This finding further illustrates the role of IDH1/2 MT in progression to a more malignant disease. Patients with ancestral IDH1 MT tended to have a worse survival than patients with subclonal IDH1 MT (23 vs 32 months, P = 0.09; Figure 4f ), whereas there was no survival difference between patients with ancestral vs subclonal IDH2 MT (33 vs 30 months, P = 0.35; Figure 4g ).
The association between IDH1 MT and IDH2 MT and overall survival was investigated separately in lower risk MDS to assess the impact on subsequent outcomes in early disease. Compared with IDH1/2 WT patients, we found that IDH2 MT patients (30 vs 66 months, P = 0.003), but not IDH1 MT patients (42 vs 66 months, P = 0.64), had a worse prognosis (Figure 4h ). Because IDH1 MT were less frequently ancestral than IDH2 MT in lower risk MDS patients (22 vs 40%), we analyzed whether ancestry of IDH1 MT impacts overall survival of lower risk MDS patients. Indeed, lower risk MDS patients with ancestral IDH1 MT had a worse survival than patients with lower risk MDS that had a subclonal IDH1 MT (23 vs 42 months, P = 0.05) or IDH1/2 WT patients (23 vs 66 months, P = 0.006; Figure 4i ). In lower risk MDS, ancestral IDH2 MT may also be associated with worse prognosis, compared with subclonal IDH2 MT . However, definitive conclusions from this subset analysis were hindered by the limited number of cases (Supplementary Figure S3 ).
DISCUSSION
In this report, we describe the clinical and molecular characterization of IDH1 MT and IDH2 MT patients with myeloid neoplasms. The size of the cohort allowed for the most comprehensive analysis to date of molecular, morphological and clinical features associated with IDH1/2 mutations, separately and combined. For the first time, a comprehensive analysis of clonal architecture distinguished ancestral from subclonal somatic lesions and determined differences in their clinical and biological impact. We demonstrate that IDH1 MT and IDH2 MT can occur as ancestral or subclonal defects. In a substantial proportion of cases, IDH1 MT (19%) and IDH2 MT (34%) represent ancestral lesions, but more often IDH1/2 MT follow other ancestral mutations as subclonal events, likely explaining higher percentages of subclonal events in advanced myeloid disease. When present in lower risk/early MDS, IDH1/2 MT are associated with a poor prognosis, while in higher risk myeloid neoplasms, prognosis could not be further stratified. Patients with ancestral IDH1 MT exhibit worse survival than those with a subclonal IDH1 MT mutation, particularly in lower risk MDS. Such a difference was not found when ancestral vs subclonal IDH2 MT were compared, indicating that IDH2 MT more rapidly dominate the clonal hierarchy.
Analyses of mutations that positively or negatively correlate with IDH1/2 MT in myeloid neoplasms have heretofore treated IDH1/2 MT cases as a single functional entity. In our cross-sectional analysis, this approach of pooling IDH1/2 MT was only adequate for their association with NPM1 mutations, and their mutual exclusivity with TET2 mutations, as these are the only lesions that were significant for both IDH1 MT and IDH2 MT separately. In addition, IDH1 MT cases were significantly enriched for DNTM3A and PHF6 mutations, and IDH2 MT cases for ASXL1, RUNX1, SRSF2 and STAG2 mutations. When IDH1/2 MT cases are pooled, all these six mutations are significantly more frequently occurring in IDH1/2 MT vs IDH1/2 WT cases. This would falsely suggest that they occur more frequently in both IDH1 MT and IDH2 MT cases, whereas the significant correlation is only true for either IDH1 MT or IDH2 MT cases. 'pAML-associated' DNMT3A and NPM1 mutations occurred significantly more frequently in IDH1 MT cases than in IDH2 MT cases, whereas the reverse was true for 'MDS/sAML/(MPN)-associated' ASXL1, RUNX1, SRSF2 and STAG2 mutations. Of note, there were no significant proportional differences with respect to diagnosis between IDH1 MT and IDH2 MT cases, with only a trend (P = 0.051) toward higher risk MDS patients among IDH2 MT cases than among IDH1 MT cases. Apparently, the functional cooperation between certain mutations (for example, DNTM3A mutations and IDH1 MT or RUNX1 mutations and IDH2 MT ) in the clonal hierarchy is driving the aforementioned positive correlations without resulting in disease phenotypes that are typical for these lesions.
The differences in at least some of the biological/clinical features between IDH1 MT and IDH2 MT cases may stem from the differences in the biochemical consequences of these lesions. For instance, the various IDH1/2 MT differ in D-2HG levels they produce, which is likely because of the impact of the specific amino acid substitutions on the catalytic site and thereby the conversion rate of αKG to D-2HG. Whereas IDH1 is cytoplasmic, IDH2 is mitochondrial and αKG levels may not be completely interchangeable between these subcellular compartments, generating different conditions for IDH1 MT and IDH2 MT to synthetize D-2HG. Furthermore, nuclear DNA and histone demethylases (for example, TET2, Jumonji) and cytoplasmic prolyl hydroxylases (EGLN) are considered to be drivers of IDH1/2 MT -induced oncogenesis, 1 suggesting that D-2HG mainly functions oncogenically outside mitochondria. It is unknown to what extent D-2HG passes the mitochondrial membrane. Therefore, the impact of the compartmentalization of αKG and D-2HG on the downstream effects of IDH2 MT vs IDH1 MT is unclear.
D-2HG functions as an oncometabolite that inhibits various αKG-dependent dioxygenases. Although the effects of D-2HG on DNA demethylase TET2, histone demethylase Jumonji and the HIF1α degrader EGLN have been described thoroughly, 9, 26, 27 there are in fact over 60 different αKG-dependent human dioxygenases involved in a plethora of cellular functions that may be inhibited, or possibly activated, as is the case with EGLN, by D-2HG. All these enzymes have specific IC 50 values of D-2HG for inhibition of αKG-dependent enzymes. Thus, each D-2HG concentration (that is, each IDH1/2 MT variant) is expected to inhibit a specific subset of αKG-dependent dioxygenases and alter cellular functions in a variety of ways.
It has been proposed that the αKG-dependent DNA demethylase TET2 is one of the most important downstream targets of IDH1/2 MT . 26,28 D-2HG inhibits TET2 and results in a genome-wide DNA hypermethylation in IDH1/2 MT cancers that induces stemness and inhibits differentiation. 7 In our cohort, and that of others, 29 IDH1/2 and TET2 mutations are mostly mutually exclusive, supporting the notion of similar cellular downstream effects. TET2 mutations, albeit rare, were more frequent in IDH1 MT cases (14%) than in IDH2 MT cases (4%). It is possible that IDH1 MT result in less TET2 inhibition than IDH2 MT and that a synergistic/additive effect of co-occuring IDH1 and TET2 mutations augments TET2 inhibition. Of note, TET2 is widely held to be a downstream element of the pathogenic cascade induced by IDH1/2 MT . Despite this, the profoundly distinct nosological and morphological spectra associated with TET2 and IDH1/2 mutations speak against this notion. Another putative important downstream target of IDH1/2 MT is UTX/ KDM6A. 7, 27 However, we did not observe mutual exclusivity between IDH1/2 and UTX mutations, suggesting that D-2HG-mediated UTX inhibition has a different effect than the UTX mutations that we observed. Notably, we did not observe a negative correlation between IDH1/2 and WT1 mutations, as previously reported. 30 Our study provides the first comprehensive subclassification of IDH1/2 MT cases with myeloid neoplasms based on their rank within clonal hierarchy, and thus their timing in clonal ontogeny. While cases initiated by IDH1/2 MT are a distinct subset of myeloid neoplasms, in many instances IDH1/2 MT are subclonal. The impact of the corresponding ancestral lesions, then, may more profoundly shape the individual neoplastic biology. This observation has clinical implications because, at least theoretically, therapeutic targeting of subclonal lesions is less likely to be curative as the ancestral clone cannot be eliminated. Remissions achieved in such cases thus have a greater likelihood of relapse, and durable clinical benefit may depend on combination therapies that also target the ancestral event(s). In addition, we report that ancestral IDH1/2 MT are related to poor clinical outcomes, whereas this association is weaker for subclonal IDH1/2 MT . These findings illustrate that patients with myeloid neoplasms carrying ancestral IDH1/2 MT are the best candidates for therapy with IDH1/2 MT inhibitors. Thus, sequencing that targets mutations frequently co-occurring with IDH1/2 MT , in particular those which are often ancestral, may aid rational clinical treatment of IDH1/2 MT patients with IDH1/2 MT inhibitors. IDH1/2 MT occur in a myriad of cancer types. Their biology in glioma and AML has been studied most intensively. The distribution of IDH1/2 MT differs between gliomas and myeloid neoplasms, and fundamental differences exist in IDH1/2 MT biology between these two tumor types. Whereas IDH1/2 MT are very early events in gliomagenesis and have even been proposed as a canonical ancestral event, 31, 32 our findings show that this is in stark contrast to myeloid neoplasms, in which IDH1/2 MT are ancestral in a minority of cases. In addition, IDH1/2 MT associate with a strikingly prolonged overall survival in glioma, 25, 33 whereas our study, and that of others, 34 showed that these mutations are associated with worse prognosis in myeloid neoplasms.
In summary, we present results that demonstrate distinct differences between IDH1 MT and IDH2 MT . The position in the clonal hierarchy may be important for understanding the impact on the biology and clinical consequences of these mutations, and may refine future treatment of IDH1/2 MT myeloid neoplasms with IDH1/2 MT inhibitors. We conclude that the minority of patients with myeloid neoplasms carrying ancestral IDH1/2 MT are the best candidates for therapy with IDH1/2 MT inhibitors.
